AUS
NZ
UK
CA
USA
IND
_06_19_2026_12_34_15_139937.jpg)
Highlights
Ondine Biomedical (LON:OBI) to present health economic research at ICPIC
Steriwave nasal photodisinfection shows strong patient outcome benefits
Research underlines hospital cost savings through infection prevention
Ondine Biomedical (LON:OBI) has announced its participation in the globally recognized International Conference on Prevention & Infection Control. The company will present findings from a health economics study that underscores the benefits of Steriwave nasal photodisinfection in reducing surgical site infections and improving hospital efficiency.
Health Economics and Infection Prevention
The research was conducted with input from a specialist health economics consortium and demonstrates that nasal photodisinfection has the potential to significantly reduce hospital-acquired infections. This outcome not only supports enhanced patient care but also helps mitigate the economic burden associated with prolonged hospital stays and additional treatments.
Clinical and Economic Impact
The analysis examined real-world cases within teaching hospital environments and further utilized modeling approaches across a range of surgical specialties. Results indicated that incorporating Steriwave nasal treatment into routine pre-surgical care offers measurable improvements in infection control strategies. Hospitals adopting such measures can potentially experience operational benefits while easing pressure on limited healthcare resources.
Steriwave Technology
Steriwave is designed as a non-invasive and pain-free solution for nasal decolonization. The process involves applying a proprietary photosensitive agent to the nostrils, followed by targeted light activation. This technique effectively neutralizes harmful pathogens including bacteria, fungi, and viruses, while preserving the natural microbiome balance.
Adoption Across Regions
The technology is already in clinical use across healthcare facilities in Canada and has seen growing uptake in the United Kingdom. The ongoing recognition at major global infection control forums further supports its expanding relevance within modern hospital environments. Additionally, regulatory progress continues across various international markets where photodisinfection is being evaluated for wider application.
Strategic Importance for Healthcare Systems
Preventing infections remains a critical factor in modern healthcare. By deploying innovative, rapid, and effective interventions, hospitals can safeguard patient health, optimize the use of resources, and contribute to the global effort in reducing antimicrobial resistance. Ondine Biomedical’s inclusion at the conference reinforces the strategic importance of its technology in addressing these pressing challenges.
Company
Ondine Biomedical (LON:OBI) is a Canadian life sciences company engaged in the development of light-activated antimicrobial therapies. Its core platform focuses on photodisinfection, with a pipeline of investigational products under evaluation for conditions ranging from respiratory infections to wound care. Steriwave, the company’s flagship nasal therapy, has already secured approvals in several regions and continues to advance through regulatory processes in additional jurisdictions.
Frequently Asked Questions
- What is Steriwave?
Steriwave is a light-activated nasal antimicrobial therapy for infection prevention. - Where is Steriwave used?
It is used in hospitals in Canada, the United Kingdom, and other regions. - What does Ondine Biomedical develop?
The company develops photodisinfection therapies for infection prevention and treatment.
